Publications

1. GVS assessment of givosiran (Givlaari®) for the treatment of acute hepatic porphyria

   The National Health Care Institute has completed its assessment whether givosiran (Givlaari®) is interchangeable with a product ...

   Report | 02-02-2021

2. GVS assessment oxybutynin intravesical solution (Vesolox®)

   Zorginstituut Nederland has completed its assessment whether oxybutynin intravesical solution (Vesolox®) 1mg/ml is ...

   Report | 18-01-2021

3. GVS advice mexiletine (Namuscla®)

   The National Health Care Institute has completed its assessment whether the product mexiletine (Namuscla®) is interchangeable ...

   Report | 13-01-2021

4. Advice on a potential candidate for conditional inclusion of rhPTH 1-84 (Natpar®) in chronic hypoparathyroidism

   Zorginstituut Nederland recommends the minister of Medical Care that rhPTH 1-84 (Natpar®) be designated as a potential candidate ...

   Letter | 21-12-2020

5. GVS advice concerning romosozumab (Evenity®) for the treatment of severe osteoporosis

   The National Health Care Institute has completed its assessment whether romosozumab (Evenity®) is interchangeable with a product ...

   Report | 16-12-2020

6. GVS assessment of amikacin liposome inhalation suspension (Arikayce® liposomal) for the treatment of NTM lung infections

   Zorginstituut Nederland has completed its assessment whether amikacin liposome inhalation suspension (Arikayce® liposomal) can be ...

   Report | 15-12-2020

7. GVS assessment - extension of further conditions for nintedanib (Ofev®)

   The National Health Care Institute has completed its assessment of the possible extension of the further conditions for ...

   Report | 15-12-2020

8. Package advice polatuzumab vedotin (Polivy®) in combination with bendamustine and rituximab (Pola-BR) for the treatment of r/r DLBCL

   Zorginstituut Nederland has completed its assessment whether polatuzumab vedotin (Polivy®) in combination with bendamustine and ...

   Report | 10-12-2020

9. GVS assessment of tafamidis (Vyndaqel®) for the treatment of wild-type or hereditary transthyretin amyloidosis

   The National Health Care Institute has completed its assessment whether tafamidis (Vyndaqel®) for the treatment of wild-type or ...

   Report | 03-12-2020

10. Advice on a potential candidate for conditional inclusion of ataluren (Translarna®) for Duchenne's muscular dystrophy

    Zorginstituut Nederland recommends that ataluren be designated as a potential candidate for conditional inclusion. Ataluren is ...

    Letter | 24-11-2020